Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent on riboflavin status: implications for riboflavin requirements.

BACKGROUND Methylenetetrahydrofolate reductase (MTHFR; EC 1.7.99.5) supplies the folate needed for the metabolism of homocysteine. A reduction in MTHFR activity, as occurs in the homozygous state for the 677C-->T (so-called thermolabile) enzyme variant (TT genotype), is associated with an increase in plasma total homocysteine (tHcy). OBJECTIVE In vitro studies suggest that the reduced activity of thermolabile MTHFR is due to the inappropriate loss of its riboflavin cofactor. We investigated the hypothesis that MTHFR activity in the TT genotype group is particularly sensitive to riboflavin status. DESIGN We studied tHcy and relevant B-vitamin status by MTHFR genotype in a cross-sectional study of 286 healthy subjects aged 19-63 y (median: 27 y). The effect of riboflavin status was examined by dividing the sample into tertiles of erythrocyte glutathionine reductase activation coefficient, a functional index of riboflavin status. RESULTS Lower red blood cell folate (P = 0.0001) and higher tHcy (P = 0.0082) concentrations were found in the TT group than in the heterozygous (CT) or wild-type (CC) groups. However, these expected relations in the total sample were driven by the TT group with the lowest riboflavin status, whose mean tHcy concentration (18.09 micromol/L) was almost twice that of the CC or CT group. By contrast, adequate riboflavin status rendered the TT group neutral with respect to tHcy metabolism. CONCLUSIONS The high tHcy concentration typically associated with homozygosity for the 677C-->T variant of MTHFR occurs only with poor riboflavin status. This may have important implications for governments considering new fortification policies aimed at the prevention of diseases for which this genotype is associated with increased risk.

[1]  H. McNulty,et al.  Low-dose vitamin B-6 effectively lowers fasting plasma homocysteine in healthy elderly persons who are folate and riboflavin replete. , 2001, The American journal of clinical nutrition.

[2]  S. Vollset,et al.  Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. , 2000, Clinical chemistry.

[3]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[4]  I. Rosenberg,et al.  Serum Total Homocysteine Concentrations in the Third National Health and Nutrition Examination Survey (19911994): Population Reference Ranges and Contribution of Vitamin Status to High Serum Concentrations , 1999, Annals of Internal Medicine.

[5]  A. Leino.  Fully automated measurement of total homocysteine in plasma and serum on the Abbott IMx analyzer. , 1999, Clinical chemistry.

[6]  D. Shields,et al.  The "thermolabile" variant of methylenetetrahydrofolate reductase and neural tube defects: An evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. , 1999, American journal of human genetics.

[7]  A. Gardemann,et al.  The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. , 1999, European heart journal.

[8]  N. Matthews,et al.  A simple, sensitive and reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[9]  D. Wilcken,et al.  Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. , 1998, Circulation.

[10]  E. Rimm,et al.  A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S. men. , 1998, Journal of the American College of Cardiology.

[11]  H. McNulty,et al.  Riboflavin and vitamin B-6 intakes and status and biochemical response to riboflavin supplementation in free-living elderly people. , 1998, The American journal of clinical nutrition.

[12]  J. Clegg,et al.  Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. , 1998, American journal of human genetics.

[13]  T. Arinami,et al.  Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. , 1998, Atherosclerosis.

[14]  L. Brattström.  Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. , 1997, Circulation.

[15]  V. Gudnason,et al.  C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. , 1997, Atherosclerosis.

[16]  S. Daly,et al.  Thermolabile variant of 5, 10-methylenetetrahydrofolate reductaseassociated with low red-cell folates: implications for folate intake recommendations , 1997, The Lancet.

[17]  P. Finglas,et al.  Relationships between micronutrient intake and biochemical indicators of nutrient adequacy in a ‘free-living’ elderly UK population , 1997, British Journal of Nutrition.

[18]  J. Yarnell,et al.  The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. , 1996, QJM : monthly journal of the Association of Physicians.

[19]  J. Burn,et al.  Methylenetetrahydrofolate reductase and neural tube defects , 1996, The Lancet.

[20]  S. Ebrahim,et al.  Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men , 1995, The Lancet.

[21]  S. Vollset,et al.  Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. , 1995, JAMA.

[22]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[23]  A M Prentice,et al.  The relative effectiveness of iron and iron with riboflavin in correcting a microcytic anaemia in men and children in rural Gambia. , 1983, Human nutrition. Clinical nutrition.

[24]  Kelleher,et al.  Microbiological assay for vitamin B 12 performed in , 2004 .

[25]  R. Matthews,et al.  The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia , 1999, Nature Structural Biology.

[26]  S. Niermeyer,et al.  Lowering blood homocysteine with folic acid based supplements: meta›analysis of randomised trials , 1998 .

[27]  J. Scott,et al.  Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. , 1997, Methods in enzymology.

[28]  I. Rosenberg,et al.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. , 1996, Circulation.

[29]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.

[30]  Dietary reference values for food energy and nutrients for the United Kingdom. Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy. , 1991, Reports on health and social subjects.

[31]  K. Pettigrew,et al.  The natural history of homocystinuria due to cystathionine beta-synthase deficiency. , 1985, American journal of human genetics.